New 6-Month TB drug cocktail could replace Year-Long ordeal
NCT ID NCT07486024
First seen Mar 27, 2026 · Last updated Jun 20, 2026 · Updated 14 times
Summary
This study tests a new 6-month treatment called BPaLM for people with multidrug-resistant tuberculosis (MDR-TB). The goal is to see if it works as well as the current 18+ month regimen. About 55 adults in France will receive the shorter treatment, and their outcomes will be compared to past patients who had standard care. If effective, this could greatly reduce treatment burden and improve quality of life for MDR-TB patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOBACTERIUM TUBERCULOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pitié-Salpêtrière Hospital - infectious and tropical diseases
Paris, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BPaLM regimen (bedaquiline, pretomanid, linezolid, moxifloxacin)
What this could lead to
If successful, this could offer a much shorter, more tolerable treatment for multidrug-resistant tuberculosis, replacing the current long and difficult regimen.
What could go wrong
This is a small, non-randomized trial comparing to historical data, so results may not be conclusive. The regimen still requires careful monitoring for side effects like nerve damage or heart issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.